The impact of frailty according to Clinical Frailty Scale on clinical outcome in patients with heart failure.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
04 2021
Historique:
revised: 14 01 2021
received: 27 10 2020
accepted: 26 01 2021
pubmed: 7 2 2021
medline: 2 7 2021
entrez: 6 2 2021
Statut: ppublish

Résumé

There is currently no gold standard in evaluating frailty in patients with heart failure (HF), and the prognostic value of frailty according to the Canadian Study of Health and Aging Clinical Frailty Scale (CFS) on mortality in patients with HF is still unknown. Among consecutive 596 patients after their discharge from HF in Kokura Memorial Hospital (Kitakyushu, Japan) during 2015, their frailty at discharge was assessed according to CFS. Patients were classified into three groups: low (N = 232, 38.9%), intermediate (N = 230, 38.6%), and high (N = 134, 22.5%). The primary endpoint was defined as 2 year all-cause death. The mean age was 76.6 ± 10.1 years, and 55.3% were men in entire cohort. There were significant differences in age, living environment, and dementia among low, intermediate, and high CFS groups. Left ventricular ejection fraction (LVEF) and co-morbidities such as severe renal failure and severe anaemia tended to increase with frailty severity, while body mass index (BMI) and albumin level tended to decrease with frailty severity. Two year cumulative incidences of all-cause death for the three groups were 12.8%, 25.4%, and 52.7% (P < 0.001), respectively. This significant difference in the risk for all-cause death among the CFS groups was driven by the risk for cardiac (8.6%, 14.2%, and 31.0%, respectively, P < 0.001) and non-cardiac death (4.6%, 13.0%, and 31.4%, respectively, P < 0.001). The multivariate analysis showed that high frailty was independently associated with all-cause death (intermediate CFS group: adjusted hazard ratio, 1.43, 95% confidence interval, 0.86-2.36, P = 0.16; high CFS group: adjusted hazard ratio, 3.90, 95% confidence interval, 2.32-6.55, P < 0.001), and this result was consistent, irrespective of stratification based on age, sex, BMI, and LVEF without significant interaction. The simple CFS tool was successful in predicting the risk for all-cause death in patients with HF, and frailty according to CFS was independently associated with all-cause death irrespective of stratification based on age, sex, BMI, and LVEF without significant interaction. The CFS is a valuable prognostic tool in clinical settings.

Identifiants

pubmed: 33547759
doi: 10.1002/ehf2.13254
pmc: PMC8006666
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1552-1561

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Eur J Prev Cardiol. 2019 Jul;26(10):1115-1117
pubmed: 30722680
ESC Heart Fail. 2021 Apr;8(2):1552-1561
pubmed: 33547759
Eur J Clin Invest. 2005 Dec;35(12):723-30
pubmed: 16313247
Eur Heart J Suppl. 2019 Dec;21(Suppl L):L12-L16
pubmed: 31885506
Aging Clin Exp Res. 2017 Oct;29(5):913-926
pubmed: 28688080
Eur J Heart Fail. 2020 Nov;22(11):2112-2119
pubmed: 32500539
Eur J Heart Fail. 2015 Sep;17(9):884-92
pubmed: 26222508
J Am Heart Assoc. 2018 Dec 4;7(23):e008251
pubmed: 30571603
J Am Med Dir Assoc. 2013 Jun;14(6):392-7
pubmed: 23764209
Circulation. 2017 May 23;135(21):2013-2024
pubmed: 28302751
JACC Heart Fail. 2019 Apr;7(4):291-302
pubmed: 30738977
Circulation. 2006 Mar 21;113(11):1424-33
pubmed: 16534009
Int J Cardiol Heart Vasc. 2018 Nov 07;21:103-106
pubmed: 30450408
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Eur J Heart Fail. 2014 Feb;16(2):173-9
pubmed: 24464911
Circ Cardiovasc Interv. 2018 Jul;11(7):e006778
pubmed: 30006333
Int J Cardiol. 2017 Jun 1;236:283-289
pubmed: 28215466
Eur J Heart Fail. 2019 Nov;21(11):1299-1305
pubmed: 31646718
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
Clin Res Cardiol. 2017 Jul;106(7):533-541
pubmed: 28204965
Circulation. 1993 Jul;88(1):107-15
pubmed: 8319323
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
ESC Heart Fail. 2020 Jun;7(3):1264-1272
pubmed: 32125785
Eur Heart J Suppl. 2019 Dec;21(Suppl L):L36-L38
pubmed: 31885512
Lancet. 1999 Jan 9;353(9147):89-92
pubmed: 10023892
J Am Coll Cardiol. 2010 Jan 26;55(4):309-16
pubmed: 20117435
ESC Heart Fail. 2018 Aug;5(4):610-619
pubmed: 29520978

Auteurs

Kenji Kanenawa (K)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Akihiro Isotani (A)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Kyohei Yamaji (K)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Miho Nakamura (M)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Yuichi Tanaka (Y)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Kaoru Hirose-Inui (K)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Shimpei Fujioka (S)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Shintaro Mori (S)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Mariko Yano (M)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Shinya Ito (S)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Takashi Morinaga (T)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Masato Fukunaga (M)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Makoto Hyodo (M)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Kenji Ando (K)

Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, 802-8555, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH